Digestive System Neoplasm Clinical Trial
Official title:
Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers
Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.
Digestive cancers account for 30% of all cancers. The most common of these colorectal cancer (CRC) is the third most common cause of cancer in the world. In the metastatic phase, patients with digestive cancers generally benefit from medical treatment based on cytotoxic chemotherapy, which can be combined with targeted therapy in certain locations. Their use is based on demonstrating a significant improvement in the overall survival of patients. However, the therapeutic choice and follow-up of these treatments as a the first line treatment and beyond remain difficult given a cruel lack of biomarkers capable of predicting the response to these different molecules upstream but also usable during treatment to evaluate their efficacy or identify the development of secondary resistance mechanisms. Indeed, the only biomarkers currently validated and used before the initiation of anti-cancer treatment to stratify patients are: - the search for mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) and neuroblastoma rat sarcoma viral oncogene (NRAS) oncogenes as predictive factors for non-response to anti-Epidermal Growth Factor receptor (EGFR) in colorectal adenocarcinomas. - the search for overexpression of the human epidermal growth factor (HER2) receptor to introduce trastuzumab treatment in esophageal adenocarcinomas. In addition, they are conventionally determined from tumor tissue, which requires an invasive biopsy or surgical sampling that is difficult to repeat over time. In this context, it seems essential to us to identify new parameters allowing a better personalization of anti-cancer treatments, by favouring blood biomarkers that have the advantage of being evaluated in a minimally invasive manner and therefore be repeated to be able to judge tumor dynamics. To this end, we propose the creation of a collection of samples that will be collected before and then under treatment in patients with digestive adenocarcinoma in the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04500990 -
MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
|
||
Completed |
NCT03549494 -
Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction
|
Phase 2 | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT03724071 -
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
|
Phase 1/Phase 2 | |
Terminated |
NCT02602067 -
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
|
Phase 1 | |
Completed |
NCT05374369 -
Retrospective Analysis of Colorectal Cancer Screening Results
|
||
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT04456140 -
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
|
Phase 1 | |
Completed |
NCT03535727 -
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06223230 -
Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors
|
N/A | |
Withdrawn |
NCT04811833 -
Gastrointestinal Anastomosis Using MonoPlus® Suture
|
||
Terminated |
NCT05160168 -
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
|
Phase 1/Phase 2 | |
Completed |
NCT04722055 -
A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China
|
||
Recruiting |
NCT05238584 -
Total Versus Partial Omentectomy in the Treatment of Gastric Cancer
|
N/A | |
Recruiting |
NCT04084249 -
ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial
|
N/A | |
Terminated |
NCT01939210 -
Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy
|
N/A | |
Recruiting |
NCT05980416 -
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
|
Phase 1 | |
Recruiting |
NCT04929015 -
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
|
N/A | |
Recruiting |
NCT04493632 -
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
|
||
Recruiting |
NCT04133324 -
C-protein Reactive for the Detection of Anastomotic Leakage After Surgery for Digestive Cancer
|